Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
fecal microbial transplantation + nivolumab
- Development stage
- Unknown
- Lead developer
- Bristol Myers Squibb
- Modality
- Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Microbial Metabolites → Microbiome-Derived Products → Microbiome Therapeutics, Synthetic Biology Platforms → Engineered Microbial Therapeutics → Microbiome Therapeutics, Fresh FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Genetically Modified Bacteria → Engineered Microbial Therapeutics → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Frozen FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Microbial Proteins → Microbiome-Derived Products → Microbiome Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics, Complex Communities → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics
- Administration
- Oral (capsule, For Fmt), Intravenous (for Nivolumab), Colonoscopic (for Fmt, Occasionally)
01
Overview
**Fecal microbial transplantation + nivolumab** is an investigational combination therapy involving the administration of fecal microbiota transplantation (FMT) from healthy or responder donors together with the monoclonal antibody nivolumab, a PD-1 immune checkpoint inhibitor. FMT introduces a diverse community of gut microbes into a patient's gastrointestinal tract, aiming to modulate the gut microbiome and enhance antitumor immunity. Nivolumab blocks the programmed cell death protein 1 (PD-1) receptor on T cells, releasing inhibitory signaling and promoting T-cell–mediated anti-tumor responses. The combination is primarily studied in advanced solid tumors, especially melanoma and non-small cell lung cancer, to overcome immunotherapy resistance by altering host microbial and immune environments. FMT is usually administered orally (capsules) or via colonoscopy, and nivolumab is administered intravenously. Clinical studies have shown that this combination may increase objective response rates and enable previously refractory patients to respond to immunotherapy while maintaining a favorable safety profile[3][5][7].
- Other names
- FMT + nivolumab
02
Targets
PDCD1 (Programmed cell death protein 1 receptor)
Beyond the preview
Go deeper on fecal microbial transplantation + nivolumab.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on fecal microbial transplantation + nivolumab.